To evaluate the Safety & Anti-dandruff efficacy of test products & test regimen in comparison to placebo & control on healthy human volunteers suffering from dandruff.

nilever Industries Pvt Ltd0 个研究点目标入组 346 人开始时间: 待定最近更新: 2023年10月16日

试验速览

暂无简介。

•1. Female and male participants in the ratio of 2:1 in general good health.
•2. Participants in the age group 18-45 years (both the ages inclusive).
•3. Participants willing to give a written informed consent and agree to come for a regular follow up visit.
•4. Participants with mild dandruff score of = 40 (adherent (ASFS) + non-adherent dandruff (non-ASFS))
•5. Participants willing to abide by and comply with the study protocol.
•6. Participants who have not participated in a similar investigation in the past three months.
•7. Participants who agree to refrain from using hair dye / hair colour /henna during the study period.
•8. Participants willing to refrain from any type of hair treatment like perming, straightening etc. during the study duration
•9. Participants willing to refrain from any other anti-dandruff treatment/ products (including lotions/ home remedies/ oils/ serum/ mask) during the course of the study
•10. Participants who agree to use test product & regimen (including hair oils).

•1. Participants who have undergone hair growth treatment within 3 months before screening into the study.
•2. Participants having any active scalp disease which may interfere in the study – dermatologist’s judgement.
•3. Participants with medicated / antidandruff oil will be excluded
•4. Participants (male) having androgenic alopecia, male pattern baldness’ not be included in study.
•5. Participants who have taken chemotherapy for cancer in the 6 months prior to start of the study or have a plan to do treatments during study.
•6. Participants (females) who are pregnant or lactating
•7. Participants who have had hair transplant.
•8. A known history or present condition of allergic response/hypersensitivity to any cosmetic ingredients and pharmaceutical products.
•9. Chronic illness which may influence the cutaneous state.
•10. Participants participating in other similar cosmetic or therapeutic trial within last three months
•11. Any history of underlying uncontrolled medical illness including diabetes mellitus, hypertension, HIV, hepatitis, severe anemia, serious disorder of heart and respiratory apparatus or any other serious medical illness.
•12. Participants (males) who are having androgenic alopecia, male pattern baldness

发起方

nilever Industries Pvt Ltd